PE20191130A1 - Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes - Google Patents

Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes

Info

Publication number
PE20191130A1
PE20191130A1 PE2019000709A PE2019000709A PE20191130A1 PE 20191130 A1 PE20191130 A1 PE 20191130A1 PE 2019000709 A PE2019000709 A PE 2019000709A PE 2019000709 A PE2019000709 A PE 2019000709A PE 20191130 A1 PE20191130 A1 PE 20191130A1
Authority
PE
Peru
Prior art keywords
lipoic acid
cholin
stabilizing
methods
ester compositions
Prior art date
Application number
PE2019000709A
Other languages
English (en)
Inventor
Shikha P Barman
Koushik Barman
William R Burns
Kathryn S Crawford
Ann-Marie Cromwick
Kevin L Ward
Original Assignee
Encore Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Vision Inc filed Critical Encore Vision Inc
Publication of PE20191130A1 publication Critical patent/PE20191130A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA BIOCOMPATIBLE QUE COMPRENDE: i) UNA SAL FARMACEUTICA TAL COMO CLORURO O YODURO DE 0,1-10% DE ESTER DE COLINA DE ACIDO LIPOICO (LACE); ii) 1-30% DE UNA CICLODEXTRINA; iii) 0,1-2% DE UN AGENTE DE AJUSTE DE LA TONICIDAD COMO EL GLICEROL; iv) 0,1-0,5% DE UN AGENTE MEJORADOR DE LA VISCOSIDAD; v) 0,003-0,010% DE UN CONSERVANTE COMO CLORURO DE BENZALCONIO; vi) 0,05% A 1% DE UNA FUENTE DE ENERGIA BIOQUIMICA COMO ALANINA; Y vii) AGUA PARA INYECCION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRASTORNOS OCULARES COMO PRESBICIA, OJO SECO, CATARATAS Y DEGENERACION MACULAR RELACIONADA CON LA EDAD
PE2019000709A 2016-09-23 2017-09-22 Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes PE20191130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662398748P 2016-09-23 2016-09-23

Publications (1)

Publication Number Publication Date
PE20191130A1 true PE20191130A1 (es) 2019-09-02

Family

ID=60190904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000709A PE20191130A1 (es) 2016-09-23 2017-09-22 Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes

Country Status (19)

Country Link
US (1) US20230135366A1 (es)
EP (1) EP3515410A1 (es)
JP (1) JP7091318B2 (es)
KR (1) KR20190065304A (es)
CN (1) CN109906076A (es)
AU (1) AU2017331591B2 (es)
BR (1) BR112019005426A2 (es)
CA (1) CA3037459A1 (es)
CL (1) CL2019000766A1 (es)
CO (1) CO2019002663A2 (es)
CR (1) CR20190148A (es)
EC (1) ECSP19020167A (es)
IL (1) IL265480B (es)
JO (1) JOP20190057A1 (es)
MX (1) MX2019003365A (es)
MY (1) MY194044A (es)
PE (1) PE20191130A1 (es)
RU (1) RU2761519C2 (es)
WO (1) WO2018055572A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
US20230331692A1 (en) * 2020-08-27 2023-10-19 Kyowa Pharma Chemical Co., Ltd. Trisulfide compound and clathrate thereof
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
DE102004060914A1 (de) 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
DK2442647T3 (en) * 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
PL2442645T3 (pl) * 2009-06-15 2015-02-27 Encore Health Llc Estry choliny
CN106455563A (zh) * 2014-03-03 2017-02-22 安可视觉公司 硫辛酸胆碱酯组合物及使用方法
CN108135842B (zh) * 2015-09-24 2022-03-18 诺华股份有限公司 硫辛酸胆碱酯组合物和生产生物相容性眼科制剂的方法

Also Published As

Publication number Publication date
RU2019111885A3 (es) 2020-12-21
BR112019005426A2 (pt) 2019-06-25
ECSP19020167A (es) 2019-07-31
IL265480B (en) 2022-09-01
AU2017331591A1 (en) 2019-04-04
WO2018055572A1 (en) 2018-03-29
RU2019111885A (ru) 2020-10-23
KR20190065304A (ko) 2019-06-11
MY194044A (en) 2022-11-09
JOP20190057A1 (ar) 2019-03-24
IL265480A (en) 2019-05-30
JP2019534864A (ja) 2019-12-05
US20230135366A1 (en) 2023-05-04
JP7091318B2 (ja) 2022-06-27
CR20190148A (es) 2019-09-09
MX2019003365A (es) 2019-11-11
CN109906076A (zh) 2019-06-18
CO2019002663A2 (es) 2019-06-11
CA3037459A1 (en) 2018-03-29
CL2019000766A1 (es) 2019-08-02
RU2761519C2 (ru) 2021-12-09
EP3515410A1 (en) 2019-07-31
AU2017331591B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
PE20191130A1 (es) Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CO2018002026A2 (es) Composiciones de insulina de rápida acción
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
AR102869A1 (es) Composiciones de insulina de rápida acción
MX2018008011A (es) Composicion y metodo para el crecimiento del cabello.
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
AR098989A1 (es) Composiciones farmacéuticas que comprenden azd9291
GT201700070A (es) Composición de activo de suavizante de tejidos
PE20171178A1 (es) Composicion de rehidratacion oral y los metodos de la misma
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
BR112015005590A2 (pt) composição para tratamento de tecidos
AR101236A1 (es) Composiciones para el cuidado oral
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
BR112015018704A2 (pt) composições compreendendo gougerotina e um inseticida
AR104590A1 (es) Composición reticulante que incluye silicato sintético estratificado
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
AR093126A1 (es) Formulaciones de liberacion modificada para oprozomib